MAGEA3 and melanoma: As shown in Figures 9A–C, in the IMvigor210 cohort (anti–PD-L1), GSE35640 cohort (MAGE-A3), and Melanoma-GSE91061 cohort (anti–PD-1), patients in the high-risk group exhibited significantly shorter overall survival than those in the low-risk group did (P < 0.05), which was consistent with the results previously observed in the TCGA and multiple GEO validation datasets.